Revance Therapeutics, Inc.·4

Mar 17, 5:56 PM ET

Joshi Abhay 4

4 · Revance Therapeutics, Inc. · Filed Mar 17, 2022

Insider Transaction Report

Form 4
Period: 2022-03-15
Joshi Abhay
Chief Operating Officer
Transactions
  • Tax Payment

    Common Stock

    2022-03-15$15.79/sh2,607$41,165120,708 total
Footnotes (1)
  • [F1]Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 22,620 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Dr. Joshi's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION